AbbVie demonstrated strong financial performance in 2024 with notable growth in its ex-Humira platform and advancements in neuroscience and oncology. However, challenges persist with Humira revenue erosion and the aesthetic market facing economic headwinds. Overall, the company is poised for robust growth in 2025 despite these challenges.

Company Guidance

During AbbVie's Fourth Quarter 2024 Earnings Conference Call, the company provided guidance highlighting robust growth expectations for 2025 and beyond. AbbVie reported full-year adjusted earnings per share of $10.12, surpassing its initial guidance midpoint by $0.49. Total net revenues for 2024 were $56.3 billion, exceeding initial guidance by over $2 billion, driven by a 4.6% operational revenue growth despite a $5 billion erosion in U.S. Humira sales. The ex-Humira platform showed remarkable performance with a sales growth of over 18% for the year and 22% growth in the fourth quarter. For 2025, AbbVie anticipates mid-single-digit revenue growth, with the ex-Humira platform expected to exceed prior peak revenue. Skyrizi and Rinvoq are projected to collectively generate nearly $24 billion in revenue in 2025, reflecting a $6 billion increase, with combined sales expected to exceed $31 billion by 2027. Neuroscience and oncology are also poised for growth, with expected sales of $10 billion and $6.3 billion in 2025, respectively. The aesthetics segment faced market challenges but is projected to deliver a high single-digit revenue CAGR through 2029. AbbVie plans to leverage its diverse portfolio and pipeline advancements, including multiple new indications and regulatory submissions, to drive sustained growth.

Record-Breaking Revenue and Growth

AbbVie delivered full-year adjusted earnings per share of $10.12, which is $0.49 above initial guidance midpoint. Total net revenues were $56.3 billion, exceeding initial guidance by more than $2 billion. Full-year revenue was up 4.6% on an operational basis.

Strong Performance of Ex-Humira Platform

Ex-Humira platform delivered full-year sales growth of more than 18% with Q4 revenue growth accelerating to 22%. Skyrizi and Rinvoq collectively are expected to generate nearly $24 billion of revenue in 2025, reflecting growth of more than $6 billion.

Robust Neuroscience and Oncology Growth

Neuroscience sales are expected to reach $10 billion in 2025, reflecting growth of $1 billion. Oncology prospects are strong with notable contributions from Venclexta, Elahere, and other assets.

Pipeline Advancements and Approvals

Recent approvals include Skyrizi in UC, Epkinly for follicular lymphoma, and new indications for Botox and Juvéderm. Over 20 early-stage deals signed in 2024, enhancing pipeline depth in immunology, oncology, and neuroscience.

---

AbbVie (ABBV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABBV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 25, 2025	2025 (Q1)	2.52 / -	2.31	―	―	―
Jan 31, 2025	2024 (Q4)	2.12 / 2.16	2.79	-22.58% (-0.63)	―
Oct 30, 2024	2024 (Q3)	2.92 / 3.00	2.95	1.69% (+0.05)	―
Jul 25, 2024	2024 (Q2)	2.57 / 2.65	2.91	-8.93% (-0.26)	―
Apr 26, 2024	2024 (Q1)	2.25 / 2.31	2.46	-6.10% (-0.15)	―
Feb 02, 2024	2023 (Q4)	2.79 / 2.79	3.6	-22.50% (-0.81)
Oct 27, 2023	2023 (Q3)	2.87 / 2.95	3.66	-19.40% (-0.71)	―
Jul 27, 2023	2023 (Q2)	2.83 / 2.91	3.37	-13.65% (-0.46)	―
Apr 27, 2023	2023 (Q1)	2.51 / 2.46	3.16	-22.15% (-0.70)	―
Feb 09, 2023	2022 (Q4)	3.56 / 3.60	3.31	8.76% (+0.29)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ABBV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 31, 2025	$175.65	$183.90	+4.70%
Oct 30, 2024	$187.68	$199.62	+6.36%
Jul 25, 2024	$173.18	$179.04	+3.38%
Apr 26, 2024	$162.92	$155.45	-4.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---